AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05415644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hrx0701 tablets
Description: High specification group HRX0701 (FDC) tablets (50 mg / 1000 mg) for a total of 2 tablets (take 1 tablet after meals or on an empty stomach).~Low-spec group HRX0701 (FDC) tablets (50 mg / 850 mg) for a total of 2 tablets (take 1 tablet after meals or on an empty stomach).
Study NCT06213974 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is non-interventional study.
Study NCT06583148 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care
Study NCT06583148 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Receive the smoke-free home program
Study NCT06583148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05502016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Model Diabetes Self-Management Education and Support
Description: Participants assigned to this arm receive an intervention that includes a culturally adapted family model diabetes self-management education and support with at least one participating family member in a faith-based organization setting.
Study NCT05502016 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Model Diabetes Self-Management Education and Support (Wait-list)
Description: Participants assigned to this arm will wait approximately 12 weeks to receive an intervention that includes a culturally adapted family model diabetes self-management education and support with at least one participating family member in a faith-based organization setting.
Study NCT06583148 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05084937 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CeliCAT form
Description: Systematic summary to support transition
Study NCT05522036 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Metvix + Dermaris
Description: Photodynamic Therapy
Study NCT05404022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored nutrition and physical activity programme
Description: Physical activity prescriptions will follow recent guidance for people with cancer and the FITT principles: Frequency (weekly sessions), Intensity (how hard), Time (session duration), and Type. Programme content, duration, and intensity will be tailored for comorbidities and other limitations.~Nutrition prescription may include any or all of the following:~1. Information on side-effects that may affect eating and their mitigation~2. Feedback on physical measures (weight loss) in relation to nutrition and treatment outcomes~3. Feedback on assessment of food intake and how to improve~4. a Macmillan booklet: advice on eating and maintaining weight throughout cancer treatments.~5. a recipe book Making the most of every bite~6. tailored oral nutritional support, including use of high calorie/protein nutrition supplementation, or other macro and micronutrient supplementation as required
Study NCT05343793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Monitoring and Feedback (EMF)
Description: Enhanced Monitoring and Feedback consists of performance data (reach, adoption, effectiveness, implementation) gathered and reported by the program on a quarterly basis. Data summaries for each program and in comparison to the entire sample, will be reflected back to participants, via dashboards, within one-month of data submission.
Study NCT05343793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIATx/MAT Academy
Description: This two-day workshop will provide participating clinics with rationale, clinical practice and program integration with MOUD (Day 1), and an overview of NIATx principles and tools (Day 2).
Study NCT05343793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIATx-Internal Facilitation (NIATx-IF)
Description: Internal facilitators will receive training (in-person or online) on how to provide coaching within their organization. For 9-months, Internal Facilitators (IFs) will: a) support teams to harness resources toward systemic change and improvement; b) employ a range of concepts and tools to provide individualized support to teams; c) help teams to practice and hone their skills to optimize performance, and d) focus on team relationships and communications.
Study NCT06292273 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Abdominis Plane Block with bupivacain Plus dexamethasone
Description: Bupivacain 0.1%, 35 ml with dexmedetomidine 0.5 µG/kg on each side
Study NCT06292273 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transversus Abdominis Plane Block with bupivacain
Description: plain bupivacaine 0.25%, 25 ml bilaterally
Study NCT05536947 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread product (standard milled)
Description: Bread rolls made from standard milled flour.
Study NCT05536947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread Product (micro-milled)
Description: Bread rolls made from micro-milled whole grain flour.
Study NCT05536947 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread Product (standard aleurone)
Description: Bread rolls made from white flour/standard milled aleurone mix
Study NCT05536947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread product (micro-milled aleurone)
Description: Bread rolls made from white flour/micro-milled aleurone mix.
Study NCT05711550 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real Neurofeedback
Description: Real Neurofeedback with visual and acoustic feedback presentation based on the EEG-signal from the participant (Signals used described in corresponding study arm). The NFB-signals are obtained from the T4 and P4 positions according to the 10-20 EEG placement consensus. NFB is done using the software package Cygnet (BEE Medic GmbH Technologies, Kirchberg, Switzerland) and for all participants the same neurofeedback-animation is used. NFB training duration is approx. 30min
Study NCT05711550 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Neurofeedback
Description: The sham neurofeedback is performed in identical fashion using the same software, feedback, electrode placement, duration as in the real neurofeedback. Only difference is that a pre-recorded EEG-dataset will be used and the feedback signal is thus independent from the brain activity of the participant.
Study NCT05014100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib tablet
Description: Subjects received orelabrutinib150mg orally once daily for a 28-day cycle. Throughout the study period, all subjects continued treatment until one of the following conditions occurred: disease progression, intolerable toxicity, death, withdrawal of informed consent, or loss of follow-up
Study NCT05014100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 25mg once daily for 21 days and rituximab 375mg/m2 for 7 days~Throughout the study period, all subjects continued treatment until one of the following conditions occurred: disease progression, intolerable toxicity, death, withdrawal of informed consent, or loss of follow-up
Study NCT04702074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine granules
Description: Bu Fei Jian Pi Hua Tan granule for syndrome of the lung and spleen qi deficiency and unclean phlegm dampness.~Yi Qi Yang Yin Qing Fei granule for syndrome of qi and yin deficiency and unclean phlegm heat.~Traditional Chinese medicine granules will be administered twice daily for 2 months.
Study NCT04702074 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Traditional Chinese medicine granules placebo
Description: Bu Fei Jian Pi Hua Tan granule placebo for syndrome of the lung and spleen qi deficiency and unclean phlegm dampness.~Yi Qi Yang Yin Qing Fei granule placebo for Syndrome of qi and yin deficiency and unclean phlegm heat.~Traditional Chinese medicine granules placebo will be administered twice daily for 2 months.~The appearance, weight, color and odor of the preparation are the same as those of experimental group.~The granule placebo consists of dextrin, bitter and 5% of the Traditional Chinese medicine granules .
Study NCT06275100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Participants will be exposed to exercise and psychoeducation. Aerobic exercise will be on a cycle ergometer tailored to their capability and will aim for a low to moderate intensity.The patients will be exercised using the intermittent protocol of alternating 1 minute moderate and 1 minute low intensity aerobic exercise. This duration can be gradually increased during subsequent sessions depending on the patient's ability. Aerobic exercise will be conducted 2- 3 times per week depending on patient's ability.~In addition, participants are expected to do strength and inspiratory muscle training in their own time.~The psychoeducation booklet and audio are designed with input from in-house clinical psychologist. The aim of the booklet is to explain the emotions they may feel whilst being in hospital, symptoms of anxiety, suggest how to manage anxiety, behavioural strategies that may help and signposting if they require further support.
Study NCT06535087 — intervention group
Intervention type: DRUG
Intervention: Subcutaneous immunotherapy / Standard Treatment for Asthma and Rhinitis
Description: 1. Subcutaneous Allergen-Specific Immunotherapy:~   * Pre-treatment: Omalizumab subcutaneous injection, with the total IgE level serving as the basis for calculating the dosage for children. The appropriate dosage of omalizumab (each dose ranging from 75 to 600 mg) and administration frequency (once every 4 weeks) are determined based on the baseline IgE (IU/mL, measured before the start of treatment) and body weight (kg).~  * Mite Allergen Preparation: (Antergen/Alutard)~2. Standard Treatment:~   * Asthma: Inhaled corticosteroids (ICS) combined with long-acting beta-2 agonists, leukotriene receptor antagonists.~  * Allergic Rhinitis: Oral antihistamines, nasal antihistamines, nasal corticosteroids, anti-leukotriene drugs, cromolyn sodium, decongestants (oxymetazoline hydrochloride), and nasal saline irrigation.
Study NCT05882851 — intervention group
Intervention type: BEHAVIORAL
Intervention: determination of the current nutritional status of patients
Description: No intervention was made on the patients. Nutritional status was recorded during the treatment process. Current nutritional status and other risk factors were compared according to recovery status after treatment.
Study NCT06283849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: strategies to break up SB
Description: Participants will be asked to implement strategies to break up their SB every hour for at least 8 hours a day for one week. Strategies will be developed through collaboration with participants during the first study interview and may include (but are not limited to): calf raises, brief (\~5 min) self-paced walking), squats, sit to stand, etc. Participants will wear an activity monitor for assessment of SB and walking. This device (activPAL, PALTechnologies, Glasgow, Scotland) is not an investigational device; it is used for monitoring sedentary behavior.
Study NCT05794867 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: clinical weaning criteria
Description: Xray chest and calculation of thr rapid shallow breathing rate
Study NCT05453474 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Whole genome amplification
Description: DNA is amplified by whole genome amplification
Study NCT06001814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-Mind One-Heart
Description: One-Mind One-Heart will include mindfulness and behavior change skills to address psychological distress, physical activity, diet, and substance use.
Study NCT06663774 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Physical Fitness Tests
Description: Ippon Reactive Agility Test (IRAT), Y-Balance Test, Upper-Quarter Y Balance Test, Flamingo Balance Test, Flamingo Balance Test, Standing Long Jump Test, 20m Sprint Test, Hand Grip Test, T-Agility Test, Nelson Hand Reaction Test, Judo Specific Fitness Test
Study NCT06663748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARX788
Description: 2.2 mg/kg IV infusion on Day 1 of each 42-day treatment cycle.
Study NCT05923060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Aminolevulinate
Description: Topical Levulan Kerastick is applied to actinic keratoses.
Study NCT05923060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Description: PDT is a technique that combines a photosensitizing drug and an intense light source to kill tumor cells.
Study NCT05923060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Red light illumination
Description: To occur post-PTD; used for activation of ALA during photodynamic therapy.
Study NCT05195996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: intravenous propranolol for case patients
Study NCT05195996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intravenous saline for placebo
Study NCT05199948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soybean Oil Foods
Description: Three food product containing 10g of soybean oil each will be consumed each day for a today of 30g of soybean oil consumed each day
Study NCT05199948 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Palm Oil Foods
Description: Three food product containing 10g of palm oil each will be consumed each day for a today of 30g of palm oil consumed each day
Study NCT06001814 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Education will be provided on behavioral cardiovascular disease risk reduction strategies, such as increasing physical activity, reducing salt intake in diet, and reduce/stop alcohol and tobacco-use.
Study NCT05343793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIATx-External Facilitation (NIATx-EF)
Description: For 9-months, organizations in the NIATx-EF study arm will work with one of 4 experienced consultant NIATx External Facilitators (EFs). The EF meets with clinic staff to plan change projects, review ongoing change efforts, discuss successes, and offer guidance on planning future change projects using PDSA cycles. The EF makes a 1-day site visit during the 1st quarter of the implementation period and leads monthly 1-hour phone calls.
Study NCT06048718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab-Deruxtecan (T-DXd)
Description: Trastuzumab-deruxtecan is a human HER2-directed antibody-drug conjugate (ADC) composed of humanized anti-HER2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) with the same amino acid sequence as trastuzumab, covalently linked to the membrane-permeable topoisomerase I inhibitor payload, DXd, an exatecan derivative, via a stable tetrapeptide-based linker, selectively cleaved within tumor cells.
Study NCT06201598 — intervention group
Intervention type: DEVICE
Intervention: Group 1 - Intervention 1
Description: Endovascular treatment of cerebral aneurysms through the implantation of p64MW HPC and p48MW HPC devices.
Study NCT05643027 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acceptance and Commitment Therapy
Description: Six-session, skills-based behavioral intervention targeting risk factors for opioid use disorder in the context of cancer
Study NCT05875064 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Restoration with resin composite and polyvinyl crown
Description: Restorative treatment of anterior primary teeth with monochromatic composite resin in single insertion through polyvinyl crowns, after selective removal of carious tissue compared to the effectiveness of conventional restoration.
Study NCT05875064 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restoration with conventional resin composite
Description: Restorative treatment of anterior primary teeth with conventional composite resin, after selective removal of carious tissue
Study NCT05455411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based Parent-implemented Training
Description: A group-based social communication training for parents of preschoolers with autism spectrum disorder will be taught by a speech therapist online (approximately 25 hours distributed over 6 months), with up to 8 parents in a group.
Study NCT05455411 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual-based Parent-implemented Training
Description: An individual-based social communication training for parents of preschoolers with autism spectrum disorder will be taught by a speech therapist online in a one-on-one format (approximately 25 hours distributed over 6 months).
Study NCT06354764 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT06409845 — intervention group
Intervention type: DRUG
Intervention: Eptinezumab 100 or 300 mg ev
Description: Patients administered eptinezumab 100 or 300 mg ev quarterly for migraine prevention
Study NCT05899777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yizhi Baduanjin
Description: Yizhi Baduanjin is a newly compiled routine developed on the foundation of the traditional Baduanjin, aiming at the mental and cerebral health of middle-aged and elderly population, which combining the preliminary research result and principles of the traditional routine. It could be practiced in long term to prevent MCI and AD, or simply as a general health exercise for elders.
Study NCT05630573 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNM001
Description: intramuscular injection
Study NCT05630573 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intramuscular injection
Study NCT05713916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention: Population Health Coordinator
Description: After being notified of the finding of LVH in their patient, the population health coordinator will offer to schedule a dedicated visit for the provider and their patient to discuss this finding through a structured correspondence. Additionally, the population health coordinator will offer to coordinate 24-hour ambulatory blood pressure monitoring before or after the patient visit as part of the evaluation of LVH. Finally, for patients without established cardiovascular care and whose etiology of LVH remains undetermined, the population health coordinator will offer to coordinate a visit with a cardiologist to discuss the finding of LVH.
Study NCT05748483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Oral Tablet
Study NCT05748483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atogepant
Description: Oral Tablet
Study NCT06071910 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ER-REBOA catheter
Description: To achieve rapid aortic occlusion
Study NCT05928065 — intervention group
Intervention type: OTHER
Intervention: Collection of datas
Description: Collection of datas: datas of physical examination (swelling, hematoma, edema), benign trauma (non deforming and closed fractures), ultrasound and radiographic images and evaluation of pain.
Study NCT06576973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adbelimumab, Albumin paclitaxel, Carboplatin, Apatinib
Description: Adbelimumab 1200mg Day 1; Albumin paclitaxel 260mg/m2, Day 1; carboplatin AUC=5, Day 1; Apatinib 250mg Po Day 2-4. Preoperative neoadjuvant therapy for 4 cycles, one cycle every 21 days.
Study NCT06576973 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Prior to each surgical procedure, the department engaged in comprehensive discussions and deliberations to ascertain and establish the most suitable course of action. Minimally invasive IvorLewis (intrathoracic anastomosis) or McKeown (neck anastomosis) esophagectomy, including two field extensive lymphadenectomies, was performed according to the tumor location. The resection length should be at least 5cm from the tumor origin according to prechemotherapy by endoscopy. The surgeries will be performed by surgeons with rich experience. Minimally invasive esophagectomy, can be performed using the da Vinci surgical robot, thoracoscope, or laparoscope, or by using an open approach, as judged appropriate by the surgeon.
Study NCT06576973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collecting samples from participant
Description: Blood, Tumour will be Collected from participant. Fate of sample is Destruction after use. 20 ml of peripheral blood was collected the day before each of the immunotherapy sessions and after surgery. Tumour sample will be collected before neoadjuvant therapy and after surgery.
Study NCT05377463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support to promote uptake and persistence of medication assisted treatment (MAT)
Description: Participants will be assigned to receive peer support to promote uptake of MAT and persistence. This component will consist of two informational sessions, a tailored recovery plan, and on-going support from a peer for the first 6 months.
Study NCT05377463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment (BAT) to reduce depression
Description: Participants will be assigned to receive BAT treatment for depression. This component will consist of 8 sessions where participants will identify short and long-term goals, values, and the activities unrelated to substance use that were previously enjoyed or are likely to increase a feeling of well-being. This intervention component focuses on making a plan to troubleshoot barriers to re-engage in these activities. Sessions are delivered weekly. The content includes psycho-education about what depression is, the intervention rationale, and the activities and monitoring of activities, building social contracts to engage networks, and discussion of potential barriers to following through with activities.